Paradox Immunotherapeutics

Reshaping the future of protein misfolding diseases.

[OBIO @OBIOscience]

Today is also a great opportunity to celebrate the incredible companies selected for our WiHI Seed Program 2023!

👏🏽@AiValidus I @atorvia_co I @CoveNeuro I @HDAXtx
I @ImaginAbleSlns I mDETECT Inc. I MoxyPatch I @NoaTherapeutics I @ParadoxImmuno I @Tenomix_Inc
I @Vessl_Pros

[OBIO @OBIOscience]

@FilomenaTassi @Charmomof5 @cozen_oconnor @EYCanada @StemCellNetwork Shout-out to #OBIO’s 2023 #WiHI Seed cohort companies who pitched at the competition! Congratulations to @Tenomix_Inc, @HDAXtx & @ParadoxImmuno on receiving investments of $100,000 each from #OBIO #WiHI! Kudos to @ImaginAbleSlns for the $15,000 non-dilutive Audience Choice Award!

[Paradox Immunotherapeutics @ParadoxImmuno]

You heard it here first! Paradox is pleased to be participating in @MassBio 2024 Align Summit w/ insights by @McKinsey & @LocustWalkPtrs. Register for a day full of partnering opps. w/ investors, panels & presentations from early-stage #Biotech companies https://t.co/WMNWNmUkym

[OBIO @OBIOscience]

Congratulations to Natalie Galant and the @ParadoxImmuno team for being #BIO2023 Emerging Start-Up Stadium winner. What a great achievement!

https://t.co/lR0sXHKVJ2

[OBIO @OBIOscience]

👏What an amazing accomplishment, @ParadoxImmuno! Last week, Paradox, an #OBIO member, was announced the winner of #BIO2023 Emerging Start-Up Stadium!

🎉Congratulations Natalie Galant and the Paradox team!

Read more👇
https://t.co/V2B97PY335

#OBIOmember #globalbiotechweek

[OBIO @OBIOscience]

👏@ParadoxImmuno is among the finalists at the Start-Up Stadium at #BIO2023. Here’s Natalie Galant, CEO and Co-founder of Paradox, presenting to a panel of investors.

[Paradox Immunotherapeutics @ParadoxImmuno]

Paradox is thrilled to announce that we have been selected as a finalist in this year's #BIO2023 Start-Up Stadium! Come see us in Boston on Wed June 7th to learn more about our R&D and recent milestones! #StandUpForScience https://t.co/ophHnSTUGO

[Vaishali Sanchorawala @vsanchorawala]

Review article on renal amyloidosis by @ahavasi1 @BU_Amyloidosis
Amyloidosis and the Kidney: An Update https://t.co/vCEBMUTusP

[Paradox Immunotherapeutics @ParadoxImmuno]

@ParadoxImmuno was proud to share its story with the viewers of @breakfasttv last week!

[Ted Rogers Centre for Heart Research @trogersresearch]

ECHO is a national entrepreneurship training program supporting heart research commercialization. We're ensuring more life-changing technologies and innovations reach patients! #HeartMonth ♥️

WATCH Dr. @SororSharifpoor discuss ECHO on @breakfasttv https://t.co/BxZOED96wt 👀

[Paradox Immunotherapeutics @ParadoxImmuno]

Thank you for the continuous support, OCI! #womeninSTEM

[Ontario Centre of Innovation (OCI) @OCInnovation]

This weekend marked the #InternationalDayofWomenandGirlsinScience and we are recognizing @ParadoxImmuno! Natalie Galant is co-founder and CEO of Paradox, a biotech company that develops immunotherapies for diseases caused by protein misfolding.
https://t.co/edfpfFgQf4

[MMI_UofT @MMI_UofT]

Thank you @ParadoxImmuno for your info session today! We really value your partnership and trust in us for #interns. It’s wonderful to see your company grow!

[Ted Rogers Centre for Heart Research @trogersresearch]

ECHO is a national entrepreneurship training program supporting heart research commercialization. We're ensuring more life-changing technologies and innovations reach patients! #HeartMonth ♥️

WATCH Dr. @SororSharifpoor discuss ECHO on @breakfasttv https://t.co/BxZOED96wt 👀

[Isabelle Lousada @i_lousada]

Calling next generation of amyloid researchers: there is much work to be done as presented by Per Westermark #ISA2018

[Sally Allain @SJAllain]

#JLABS #JLABSDC @ParadoxImmuno

[Canada in SF 🇨🇦 @CanCGSF]

The fall 2022 CTA Health kicks off this week! Congrats to the 6 Canadian startups in the cohort:

- BioStream Diagnostics
@nanotessinc
@ModelisLabs
- Nimble Science
@ParadoxImmuno
@PragmaClin

To celebrate, we will profile each this week. Follow along! #CTAConnects #cdntech

[Canada in SF 🇨🇦 @CanCGSF]

CTA health participant @ParadoxImmuno is an orphan drug, preclinical-stage platform company dedicated to the creation of antibody therapies for the treatment of rare diseases caused by protein misfolding. Learn more about them: https://t.co/qjsnFNAMoU

[Canada à SF 🇨🇦 @CGCanSF]

.@ParadoxImmuno , une entreprise participante à CTA Health, est une plateforme de médicaments orphelins, au stade préclinique, engagée en création de thérapies par anticorps pour le traitement des maladies rares causées par le mauvais repliement des protéines.

[JLABS @JLABS]

Kicking off our one-on-one video series, hear from Natalie Galant, CEO & co-founder of @ParadoxImmuno, on the rare disease startup’s strong footprint created with #JLABS global network. Watch here & tune in for more videos coming soon: https://t.co/NtMgPtUzgR

[JLABS @JLABS]

Your daily dose of inspiration delivered by the tremendous healthcare innovators at #JLABSDC! 👏🏻@AccGenetics @adipomics @algometRx @CorVistaHealth @CurrentSurgical @gabismartcare @ParadoxImmuno, @nanochan, & Tiny Cargo of @virginiatech. Learn more: https://t.co/EkWFoThw1x

[JLABS @JLABS]

Have you met @ParadoxImmuno, Fibrocor Therapeutics or ArtisanBio yet?

Don’t miss your chance to get to know 3 of the newest #JLABSToronto family members during their quick pitches & panel on 2/10. @SafeDoze & @MelindaRichter will be there- will you? https://t.co/haoR4cgfcT